Inactive Instrument

IQnovate Ltd Stock National Stock Exchange of Australia

Equities

End-of-day quote National Stock Exchange of Australia
- - Intraday chart for IQnovate Ltd
Harvard Wyss Institute’S Erapid Sensor Technology Licensed to Antisoma Therapeutics to Facilitate Infectious and Immune Disease and Cancer Diagnostics CI
The Iq Group Global Ltd. Reports Earnings Results for the Full Year Ended June 30, 2021 CI
The iQ Group Global Ltd. Auditor Raises 'Going Concern' Doubt CI
The Iq Group Global Ltd. Reports Earnings Results for the Half Year Ended December 31, 2020 CI
The Iq Group Global Ltd. Reports Earnings Results for the Full Year Ended June 30, 2020 CI
The Iq Group Global Ltd. Reports Earnings Results for the Half Year Ended December 31, 2019 CI
IQnovate Ltd will Change its Name to The iQ Group Global Ltd CI
Iqnovate Limited Reports Earnings Results for the Full Year Ended June 30, 2019 CI
Iqnovate Ltd. Reports Earnings Results for the Half Year Ended December 31, 2018 CI
IQnovate Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2018 CI
IQnovate Limited announced that it has received AUD 1.693483 million in funding a group of investors CI
IQnovate Limited Reports Unaudited Consolidated Earnings Results for the Year Ended June 30, 2018 CI
IQnovate Limited announced that it has received AUD 0.60775 million in funding CI
IQnovate Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2017 CI
IQnovate Ltd. Reports Consolidated Earnings Results for the Year Ended June 30, 2017 CI
More news
Managers TitleAgeSince
Chief Executive Officer 60 11-03-07
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 71 11-07-27
Chief Executive Officer 60 11-03-07
Director/Board Member 55 11-03-07
More insiders
The IQ Group Global Ltd is an Australia-based life sciences and medical technology company. The Company is engaged in providing intellectual asset property management services, and integrated scientific advisory to the biopharmaceutical industry. It finds, funds and develops bioscience discoveries to create medical innovations and provide the fundamental basis for pharmaceuticals and devices that global populations of patients, hospitals and healthcare providers rely. Its platform technology, TEX Core is focused to develop compounds that are designed to be tumor localizing, well-tolerated, magnetic resonance imaging (MRI)-detectable in multiple solid tumors, including cancer cells that fail to respond to therapies. The Biosensor platform is a small, organic strip that puts accurate, timely diagnosis to patients and their primary health practitioners. The Company's platform is used for multiple diagnostic tests and translation medicine.
Sector
-
More about the company